AMED - Amedisys Inc Stock Price, Fair Value and News

94.00USD+1.64 (+1.78%)Market Closed

Market Summary

USD94.00+1.64

Market Closed

1.78%

AMED Alerts

Big fall in earnings (Y/Y)

AMED Stock Price

View Fullscreen

AMED RSI Chart

AMED Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-149.16

Price/Sales (Trailing)

1.36

EV/EBITDA

37.85

Price/Free Cashflow

31.42

AMED Price/Sales (Trailing)

AMED Profitability

EBT Margin

1.44%

Return on Equity

-1.8%

Return on Assets

-0.99%

Free Cashflow Yield

3.18%

AMED Fundamentals

AMED Revenue

Revenue (TTM)

2.2B

Rev. Growth (Yr)

2.7%

Rev. Growth (Qtr)

0.11%

AMED Earnings

Earnings (TTM)

-20.6M

Earnings Growth (Yr)

-42.96%

Earnings Growth (Qtr)

-25.47%

Breaking Down AMED Revenue

Last 7 days

0.4%

Last 30 days

-0.3%

Last 90 days

-1.7%

Trailing 12 Months

15%

How does AMED drawdown profile look like?

AMED Financial Health

Current Ratio

1.09

Debt/Equity

0.31

Debt/Cashflow

0.29

AMED Investor Care

Shares Dilution (1Y)

0.36%

Diluted EPS (TTM)

-0.64

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.3B	0	0	0
2023	2.2B	2.2B	2.2B	2.2B
2022	2.2B	2.2B	2.2B	2.2B
2021	2.1B	2.2B	2.2B	2.2B
2020	2.0B	2.0B	2.0B	2.1B
2019	1.7B	1.8B	1.9B	2.0B
2018	1.5B	1.6B	1.6B	1.7B
2017	1.5B	1.5B	1.5B	1.5B
2016	1.3B	1.4B	1.4B	1.4B
2015	1.2B	1.2B	1.2B	1.3B
2014	1.2B	1.2B	1.2B	1.2B
2013	1.4B	1.4B	1.3B	1.2B
2012	1.5B	1.5B	1.5B	1.4B
2011	1.6B	1.5B	1.5B	1.5B
2010	1.5B	1.6B	1.6B	1.6B
2009	1.3B	1.4B	1.4B	1.5B
2008	0	861.1M	1.0B	1.2B
2007	0	0	0	697.9M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amedisys Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	samuels ivanetta davis	acquired	-	-	1,678	-
May 03, 2024	kline teresa l.	acquired	-	-	1,678	-
May 03, 2024	coye molly joel	acquired	-	-	1,678	-
May 03, 2024	klapstein julie d	acquired	-	-	1,678	-
May 03, 2024	perkins bruce d	acquired	-	-	1,678	-
May 03, 2024	kusserow paul b. k.	acquired	-	-	1,678	-
May 03, 2024	guidroz allyson	sold (taxes)	-26,058	92.08	-283	chief accounting officer
May 03, 2024	rideout jeffrey a	acquired	-	-	1,678	-
May 03, 2024	capps vickie l	acquired	-	-	1,678	-
Feb 20, 2024	north michael paul	sold (taxes)	-149,061	93.69	-1,591	chief information officer

Which funds bought or sold AMED recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-8.24	-319,000	2,566,000	-%
May 07, 2024	Headlands Technologies LLC	reduced	-43.00	-4,253	5,253	-%
May 07, 2024	Susquehanna Portfolio Strategies, LLC	sold off	-100	-2,153,680	-	-%
May 07, 2024	SEI INVESTMENTS CO	reduced	-4.44	-84,426	1,053,370	-%
May 07, 2024	Inspire Investing, LLC	reduced	-4.75	-29,581	357,028	0.04%
May 07, 2024	Bank Pictet & Cie (Europe) AG	unchanged	-	-31,531	1,002,060	0.03%
May 07, 2024	Swiss National Bank	added	5.4	126,938	5,935,100	-%
May 07, 2024	Cornerstone Planning Group LLC	reduced	-27.87	-3,493	8,104	-%
May 07, 2024	Arizona State Retirement System	added	3.47	2,606	826,491	0.01%
May 06, 2024	Parallel Advisors, LLC	added	754	232,009	263,854	0.01%

Are Funds Buying or Selling AMED?

Are funds buying AMED calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMED

No. of Funds

AMED Alerts

Big fall in earnings (Y/Y)

Unveiling Amedisys Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.86%	3,218,592	SC 13G/A
Feb 12, 2024	flynn james e	0%	0	SC 13G/A
Feb 08, 2024	wellington management group llp	0.00%	24	SC 13G/A
Jan 24, 2024	blackrock inc.	9.1%	2,964,393	SC 13G/A
Jul 06, 2023	jpmorgan chase & co	2.3%	774,361	SC 13G/A
May 18, 2023	flynn james e	5.51%	1,794,000	SC 13G
Feb 14, 2023	ameriprise financial inc	3.39%	1,100,719	SC 13G/A
Feb 09, 2023	vanguard group inc	9.63%	3,128,416	SC 13G/A
Feb 06, 2023	wellington management group llp	8.63%	2,802,831	SC 13G/A
Jan 26, 2023	blackrock inc.	12.6%	4,106,566	SC 13G/A

Recent SEC filings of Amedisys Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
Apr 26, 2024	10-K/A	Annual Report

Peers (Alternatives to Amedisys Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	463.9B	371.6B	9.96%	1.73%	20.73	1.25	14.64%	11.24%
CI	98.7B	206.0B	-4.33%	31.01%	25.6	0.48	12.55%	-43.95%
HCA	81.0B	66.7B	-4.37%	13.20%	14.81	1.21	9.59%	-4.59%
CVS	68.9B	360.9B	-25.27%	-20.02%	9.41	0.19	9.07%	78.49%
CNC	40.5B	155.5B	4.29%	11.16%	14.8	0.26	6.34%	84.42%
DVA	11.9B	12.3B	3.05%	54.33%	14.61	0.97	5.77%	58.74%
UHS	11.7B	14.3B	-2.27%	18.37%	16.36	0.82	6.59%	6.24%
MID-CAP
CHE	8.6B	2.3B	-7.98%	4.98%	30.5	3.77	5.96%	18.29%
ACHC	6.1B	3.0B	-11.24%	-2.13%	-542.08	2.05	10.92%	-104.06%
AMN	2.3B	3.8B	3.83%	-33.34%	10.84	0.6	-27.73%	-52.50%
AMEH	2.1B	1.4B	-9.08%	8.52%	34.78	1.52	21.19%	34.42%
SMALL-CAP
ADUS	1.8B	1.1B	2.42%	25.02%	26.69	1.61	11.45%	30.74%
BKD	1.3B	3.0B	8.71%	84.46%	-7.02	0.44	6.74%	20.73%
BEAT	54.0M	-	-2.35%	-2.35%	-3.69	-	-	-12.94%
AMS	19.4M	21.3M	10.24%	15.77%	36.46	0.91	8.00%	-62.25%

Amedisys Inc News

Latest updates

Amedisys Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	0.1%	571	571	556	553	556	562	558	558	545	559	553	564	537	551	544	485	492	501	495	493	467
Costs and Expenses	0.6%	540	537	514	515	514	516	519	510	497	511	497	491	477	495	486	458	448	459	448	448	423
EBITDA Margin	-5.5%	0.04*	0.04*	0.04*	0.04*	0.09*	0.09*	0.10*	0.11*	0.13*	0.14*	0.15*	0.16*	-	-	-	-	-	-	-	-	-
Interest Expenses	-1.4%	8.00	8.00	8.00	8.00	8.00	6.00	5.00	8.00	3.00	3.00	3.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	4.00	4.00	3.00
Income Taxes	23.6%	13.00	10.00	12.00	18.00	10.00	10.00	9.00	11.00	12.00	13.00	11.00	29.00	18.00	16.00	-10.20	10.00	9.00	11.00	10.00	10.00	11.00
Earnings Before Taxes	-6.8%	27.00	29.00	38.00	-62.23	35.00	41.00	35.00	40.00	44.00	47.00	56.00	109	68.00	62.00	62.00	45.00	41.00	39.00	44.00	44.00	42.00
EBT Margin	-18.9%	0.01*	0.02*	0.02*	0.02*	0.07*	0.07*	0.07*	0.08*	0.12*	0.13*	0.13*	0.14*	-	-	-	-	-	-	-	-	-
Net Income	-25.5%	14.00	19.00	26.00	-80.28	25.00	32.00	26.00	30.00	32.00	34.00	45.00	80.00	50.00	45.00	72.00	35.00	32.00	28.00	34.00	34.00	31.00
Net Income Margin	-111.3%	-0.01*	0.00*	0.00*	0.00*	0.05*	0.05*	0.05*	0.06*	0.09*	0.09*	0.10*	0.11*	-	-	-	-	-	-	-	-	-
Free Cashflow	-115.8%	-9.21	58.00	-10.83	59.00	25.00	39.00	-15.19	56.00	48.00	4.00	60.00	67.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	1.4%	2,090	2,060	2,027	1,982	1,947	1,976	1,982	2,001	1,908	1,857	1,938	1,600	1,573	1,567	1,603	1,645	1,440	1,263	1,212	1,206	1,184
Current Assets	5.9%	526	497	467	427	406	389	389	395	392	357	433	391	380	362	411	450	468	351	300	276	272
Cash Equivalents	-14.5%	108	127	78.00	95.00	69.00	54.00	31.00	49.00	71.00	46.00	128	93.00	78.00	83.00	115	180	178	96.00	21.00	14.00	11.00
Net PPE	2.0%	43.00	42.00	40.00	36.00	33.00	16.00	17.00	18.00	17.00	18.00	20.00	21.00	22.00	24.00	24.00	25.00	26.00	28.00	30.00	30.00	30.00
Goodwill	0%	1,245	1,245	1,245	1,245	1,245	1,287	1,285	1,290	9.00	1,196	1,188	937	933	933	931	937	721	659	660	665	650
Liabilities	0.7%	947	940	934	922	814	870	913	962	888	881	989	724	784	756	845	923	760	621	609	643	663
Current Liabilities	2.4%	485	474	468	462	353	356	367	427	380	374	454	449	456	456	437	442	316	327	315	313	297
Long Term Debt	-1.6%	356	362	367	370	373	419	443	442	429	432	435	179	231	205	301	393	380	232	232	266	304
LT Debt, Current	2.5%	37.00	36.00	-	-	-	-	-	-	-	-	-	-	-	10.00	-	-	-	10.00	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	205	-	-	-	232	-	-	-
Shareholder's Equity	2.0%	1,088	1,067	1,040	1,061	1,133	1,107	1,070	1,039	1,021	976	949	876	790	811	758	722	680	642	603	563	521
Retained Earnings	1.9%	762	748	729	703	783	758	726	700	671	639	605	560	480	430	385	313	278	246	219	185	151
Additional Paid-In Capital	1.0%	795	787	777	769	759	755	751	743	737	728	721	714	707	698	690	666	656	645	635	623	614
Accumulated Depreciation	3.9%	96.00	92.00	94.00	91.00	105	101	102	100	99.00	97.00	100	99.00	98.00	95.00	102	101	98.00	96.00	101	99.00	97.00
Shares Outstanding	0.0%	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	33.00	-	-	-	-	-	-	-	-	-
Minority Interest	2.3%	54.00	53.00	54.00	54.00	54.00	55.00	54.00	53.00	54.00	45.00	44.00	2.00	1.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
Float	-	-	-	-	2,600	-	-	-	3,000	-	-	-	6,900	-	-	-	5,500	-	-	-	2,800	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-110.8%	-6,541	60,311	-9,843	60,759	25,961	40,883	-13,630	57,409	48,621	5,166	61,767	67,958	54,002	65,912	83,083	133,922	6,035	75,220	47,455	59,266	20,059
Share Based Compensation	-16.1%	7,886	9,400	7,243	9,108	3,273	610	3,495	5,148	7,347	5,940	4,397	6,156	7,307	6,972	7,124	6,725	5,909	6,589	6,298	5,538	6,615
Cashflow From Investing	-50.5%	-3,068	-2,039	-1,048	-7,745	45,896	-1,866	-1,033	-75,508	-16,079	-11,667	-264,561	-3,822	-1,557	-1,565	-1,221	-213,567	-70,755	-1,386	-3,604	-19,046	-328,912
Cashflow From Financing	36.3%	-8,550	-13,425	-6,254	-10,953	-56,890	-16,344	-2,641	-4,046	-7,402	-75,938	238,356	-49,834	-57,458	-96,443	-146,736	82,160	146,042	1,899	-36,996	-36,872	299,178
Buy Backs	-	-	-	-	-	-	-	-	17,351	-	14,999	10,805	1,188	72,886	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AMED Income Statement

2024-03-31

CONSOLIDATED INCOME STATEMENT - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 571,414	$ 556,389
Cost of service, inclusive of depreciation	321,537	315,010
General and administrative expenses:
Salaries and benefits	127,946	126,339
Non-cash compensation	7,433	3,273
Merger-related expenses	20,667	720
Depreciation and amortization	4,271	4,443
Other	57,941	64,225
Total operating expenses	539,795	514,010
Operating income	31,619	42,379
Other income (expense):
Interest income	1,727	406
Interest expense	(8,119)	(7,517)
Equity in earnings from equity method investments	910	123
Miscellaneous, net	1,090	(682)
Total other expense, net	(4,392)	(7,670)
Income before income taxes	27,227	34,709
Income tax expense	(12,633)	(9,800)
Net income	14,594	24,909
Net (income) loss attributable to noncontrolling interests	(194)	337
Net income attributable to Amedisys, Inc.	$ 14,400	$ 25,246
Basic earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders	$ 0.44	$ 0.78
Weighted average shares outstanding, basic (shares)	32,670	32,558
Diluted earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders	$ 0.44	$ 0.77
Weighted average shares outstanding, diluted (shares)	32,979	32,643

AMED Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 108,234	$ 126,450
Restricted cash	12,470	12,413
Patient accounts receivable	359,359	313,373
Prepaid expenses	20,332	14,639
Other current assets	26,053	30,060
Total current assets	526,448	496,935
Property and equipment, net of accumulated depreciation of $96,056 and $92,422	42,684	41,845
Operating lease right of use assets	88,425	88,939
Goodwill	1,244,679	1,244,679
Intangible assets, net of accumulated amortization of $15,128 and $14,008	101,778	102,675
Other assets	85,857	85,097
Total assets	2,089,871	2,060,170
Current liabilities:
Accounts payable	36,249	28,237
Payroll and employee benefits	131,631	136,835
Accrued expenses	147,464	140,049
Termination fee paid by UnitedHealth Group	106,000	106,000
Current portion of long-term obligations	37,232	36,314
Current portion of operating lease liabilities	26,284	26,286
Total current liabilities	484,860	473,721
Long-term obligations, less current portion	356,080	361,862
Operating lease liabilities, less current portion	62,220	62,751
Deferred income tax liabilities	43,229	40,635
Other long-term obligations	828	1,418
Total liabilities	947,217	940,387
Commitments and Contingencies—Note 7
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding	0	0
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,146,546 and 38,131,478 shares issued; 32,676,115 and 32,667,631 shares outstanding	38	38
Additional paid-in capital	795,063	787,177
Treasury stock, at cost, 5,470,431 and 5,463,847 shares of common stock	(469,243)	(468,626)
Retained earnings	762,325	747,925
Total Amedisys, Inc. stockholders’ equity	1,088,183	1,066,514
Noncontrolling interests	54,471	53,269
Total equity	1,142,654	1,119,783
Total liabilities and equity	$ 2,089,871	$ 2,060,170

About Amedisys Inc

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through four segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

CEO	Mr. Richard M. Ashworth
WEBSITE	amedisys.com
INDUSTRY	Healthcare Plans
EMPLOYEES	20000

Amedisys Inc Frequently Asked Questions

What is the ticker symbol for Amedisys Inc? What does AMED stand for in stocks?

AMED is the stock ticker symbol of Amedisys Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amedisys Inc (AMED)?

As of Tue May 07 2024, market cap of Amedisys Inc is 3.02 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMED stock?

You can check AMED's fair value in chart for subscribers.

What is the fair value of AMED stock?

You can check AMED's fair value in chart for subscribers. The fair value of Amedisys Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amedisys Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMED so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amedisys Inc a good stock to buy?

The fair value guage provides a quick view whether AMED is over valued or under valued. Whether Amedisys Inc is cheap or expensive depends on the assumptions which impact Amedisys Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMED.

What is Amedisys Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, AMED's PE ratio (Price to Earnings) is -146.56 and Price to Sales (PS) ratio is 1.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMED PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amedisys Inc's stock?

In the past 10 years, Amedisys Inc has provided 0.213 (multiply by 100 for percentage) rate of return.